By Joshua Kirby

 

Novartis AG said Monday that an integrated trial of denosumab, a proposed biosimilar developed by its subsidiary Sandoz, generated positive results.

Denosumab is indicated for the treatment of various conditions including osteoporosis.

An integrated Phase 1-3 study of the biosimilar met its primary endpoints of matching reference medicines and contributing to demonstration of similarity, the Swiss drugmaker said.

 

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

 

(END) Dow Jones Newswires

September 19, 2022 01:51 ET (05:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Oct 2022 a Nov 2022 Haga Click aquí para más Gráficas Novartis.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Nov 2021 a Nov 2022 Haga Click aquí para más Gráficas Novartis.